Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2026-05-15 Earnings Release
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
Earnings Release Classification · 92% confidence The document is a Form 6-K filed by a foreign private issuer that attaches a press release titled “Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights.” The bulk of the text consists of key quarterly financial figures, business highlights, and forward-looking statements for the three months ended March 31, 2026. This matches our definition of an Earnings Release (ER): an initial announcement of quarterly/periodical financial results with key highlights. Q1 2026
2026-05-15 English
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
Report Publication Announcement Classification · 95% confidence The document is a short ISA/TASE filing under Regulation 5, notifying investors that the company has attached its Q1 2026 financial results report (“Attached hereto is a report on … results for the first quarter of 2026”), without containing the actual financial statements. It fits the “Report Publication Announcement” profile since it merely announces and links to the full report. Classification: RPA.
2026-05-15 English
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
Regulatory Filings Classification · 28% confidence The document is a corporate press release announcing new preclinical data on Purple Biotech’s lead tri-specific antibody candidate. It does not present financial results (quarterly or annual), a regulatory form, board changes, or other specific filings like an earnings release or investor presentation. It is a general announcement of scientific/clinical development, so it falls into the fallback category for miscellaneous regulatory announcements (RNS).
2026-04-27 English
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
Report Publication Announcement Classification · 90% confidence The document is a short Israeli Securities Authority/Tel Aviv Stock Exchange immediate report stating “Attached hereto is a report” and providing a PDF filename. It contains no substantive financial data or narrative but simply announces that a report has been published. Under the “menu vs meal” rule, this is an announcement of a report, not the report itself.
2026-04-27 English
“Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
Regulatory Filings Classification · 82% confidence The document is a SEC Form 6-K report by a foreign private issuer (Purple Biotech Ltd.) attaching a press release (Exhibit 99.1) announcing the establishment of a Scientific Advisory Board. It is not an annual or interim financial report, earnings release, management change notice (it establishes an external advisory board rather than directors or executives), or other specific corporate action category. As a public regulatory filing with no more specific classification, it falls into the fallback category for general regulatory announcements.
2026-04-23 English
“Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
Report Publication Announcement Classification · 85% confidence The document is an Israeli TASE/ISA immediate filing indicating “Attached hereto is a report on…” and providing a PDF reference. It does not contain the full report content but announces its publication/attachment. Under the “menu vs meal” rule, this is an announcement of a report rather than the report itself, so it should be classified as a Report Publication Announcement (RPA).
2026-04-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.